Sep 24 2026
Healthcare
Recent Research
hVIVO, H1 2026 results
Sep 15 2026
hVIVO, Acquisition of CRS Berlin
Aug 27 2026
Malin Corporation, H1 2026 results
Aug 26 2026
Uniphar, Interim trading statement
Jul 28 2026
Meet your Healthcare Research team
CVS Group
FY2026 results
CVS previously provided details on its FY2026 results to June 30th in its July trading statement. Overall, the results are in line with our forecasts and the outlook for FY2027 is to...
hVIVO
H1 2026 results
hVIVO’s H1 2026 results had largely already been given in its July trading statement. The order book is rebounding as commercial activity improves and is supported by the post...
Uniphar
H1 2026 results reflect 11% EPS growth
Uniphar provided a lot of the details on its H1 results in its July trading update. EPS growth of 11% is the standout metric, driven by strong organic growth in gross profit. The company...
hVIVO
Acquisition of CRS Berlin
hVIVO has announced the acquisition of CRS (Clinical Research Services) Berlin for a nominal upfront consideration and potential earn-out. It is a strategic bolt-on acquisition that has...
Malin Corporation
H1 2026 results
Malin has reported its H1 2026 results reflecting a NAV/share of €9.36, which is 2% growth during the period. However, the company previously reported on July 27th that it was writing...
Uniphar
Interim trading statement
Uniphar’s trading statement for H1 2026 reflects strong operating performance. The outlook is positive on all divisions. The timing of going live on Greenogue II has been extended to...
Malin Corporation
Update on contingent consideration receivable regarding Kymab
Malin has provided an update on its contingent consideration receivable regarding its former investee company, Kymab. Following a decision by Kymab’s owner, Sanofi, Malin will reduce the...
hVIVO
H1 2026 trading update
hVIVO has issued a trading update for H1 2026. Earnings are in line with expectations. There has been an increase in commercial momentum with a significant expansion in the orderbook....
CVS Group
FY2026 trading statement
CVS has issued a trading statement for FY2026, reflecting results that are in line with our forecasts. There was positive EPS growth in FY2026 despite weak consumer spending in the...
CVS Group
Announcement of share buyback
CVS has announced that it is commencing a share buyback of up to £50m (6% of its market cap). This is positive. There has been further progress on acquisitions in Australia, and CVS...
